Overview

Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM

Status:
Not yet recruiting
Trial end date:
2024-06-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of mitoxantrone hydrochloride liposome injection in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
Phase:
Phase 1
Details
Lead Sponsor:
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Treatments:
BB 1101
Bortezomib
Dexamethasone
Dexamethasone acetate
Mitoxantrone